Economic Impact of Targeted and Immunotherapies in Treating Operable Esophageal and Non-Small Cell Lung Cancers.

ABSTRACT:

Background

As the therapeutic landscape evolves, we aim to evaluate the cost implications of National Comprehensive Cancer Network-recommended perioperative targeted/immunotherapies for non-small cell lung cancers (NSCLCs) and esophageal cancers.

Methods

The Medicare Part B payment allowance limits of treatment were ascertained. Using published data, we estimated the annual incidence of eligible patients. We applied the estimated cost of the medication based on treatment dosing and duration. The costs per patient and incident cohort were calculated.

Results

We estimated that 8602 patients with newly diagnosed esophageal cancers would be eligible for adjuvant nivolumab. The cost to treat 1 patient was $190,000, and the cost to treat 1 incident cohort was $1.6 billion.

SUBMITTER: Alwatari Y 

PROVIDER: S-EPMC12711689 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature